Scribd
Upload
19 views2 pages

META

This document discusses a meta-analysis evaluating the efficacy and safety of Finerenone in preventing cardiovascular events in patients with Type 2 Diabetes Mellitus and chronic kidney disease. It includes randomized controlled trials and outlines the search strategy for relevant studies. Additionally, it references new and previous meta-analyses related to Finerenone's effects on cardiovascular and kidney outcomes.

Uploaded by

hksina.khan
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
19 views2 pages

META

This document discusses a meta-analysis evaluating the efficacy and safety of Finerenone in preventing cardiovascular events in patients with Type 2 Diabetes Mellitus and chronic kidney disease. It includes randomized controlled trials and outlines the search strategy for relevant studies. Additionally, it references new and previous meta-analyses related to Finerenone's effects on cardiovascular and kidney outcomes.

Uploaded by

hksina.khan
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 2

TOPIC SELECTION

Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2


Diabetes Mellitus With Chronic Kidney Disease: A Meta-analysis of Randomized
Controlled Trials (2023)
https://journals.lww.com/cardiovascularpharm/abstract/2023/01000/efficacy_and_safet
y_of_finerenone_for_prevention.8.aspx

P= patients of DM2 with chronic kidney disease

I= Finerenone

C= Placebo

O= major adverse cardiac events, non-fatal MI, non-fatal stroke, all-cause mortality,
hospitalization from HF.

INCLUDED RCTS

1. Bakris, 2015
2. Katayama, 2017
3. Bakris, 2020
4. Pitt, 2021

SEARCH STRATEGY

(Finerenone OR mineralocorticoid receptor antagonist OR MRA) AND


(cardiovascular diseases OR cardiovascular events OR major adverse
cardiovascular events OR MI) AND (diabetes mellitus type 2 OR DM2)
AND (DM2KD OR diabetic nephropathy) AND (safety OR efficacy)
NEW RCTS

Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc
analysis of two phase 3, multicentre, double-blind trials (2024)
https://pubmed.ncbi.nlm.nih.gov/38508632/

Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A
FIDELITY Subgroup Analysis (2023)

https://pubmed.ncbi.nlm.nih.gov/36927680/

Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and
Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis (2023)
https://pubmed.ncbi.nlm.nih.gov/37708857/
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-
Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis (2022)

https://pubmed.ncbi.nlm.nih.gov/35972218/

PREVIOUS META

Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease (2022)

https://pubmed.ncbi.nlm.nih.gov/35034019/

Effect of finerenone on cardiovascular events in kidney disease and/or diabetes: a meta


analysis of randomized control trials (2022)

https://link.springer.com/article/10.1007/s11255-022-03432-w

You might also like